Telephone sharing button Contact Us linkedin sharing button Share wechat sharing button Share wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

WuXiBody®

Launching A New Era in Bispecific Antibody Drug Development
6-18 months faster development and no
CMC challenges

WuXiBody® is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce production costs.  The WuXiBody® platform enables almost any monoclonal antibody (mAb) sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).


  • Saves 6-18 months of development time
  • Reduces manufacturing costs by as much as 90%
  • Can be used in both fed-batch and concentrated fed-batch production
  • High protein expression in CHO cells (5 g/L in fed-batch, 35 g/L in concentrated fed-batch)
  • No aggregation issues
  • Very stable: >2 weeks in serum at 37 °C
  • No solubility issues: > 30 mg/ml
WuXiBody® Platform - A New Era in Bispecifics
  • Compatible with almost any mAb sequence
  • Available in both symmetric and asymmetrical formats
  • Accommodate different valency formats (bi, tri and tetra) based on project needs and biology
  • Same purification schemes as for mAbs
  • Long In vivo half-life
  • Expected low immunogenicity (utilizes natural human sequence without complicated engineering)
WuXiBody® Platform - A New Era in Bispecifics